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Large spatial scalesChemicals released into freshwater systems threaten ecological functioning and may put aquatic life and the
health of humans at risk. We developed a new contaminant fate model (CFM) that follows simple, well-
establishedmethodologies and is unique in its cross-border, seamless hydrological and geospatial framework, in-
cluding lake routing, a critical component in northern environments. We validated themodel using the pharma-
ceutical Carbamazepine and predicted eco-toxicological risk for 15 pharmaceuticals in the Saint-Lawrence River
Basin, Canada. The results indicated negligible to low environmental risk for the majority of tested chemicals,
while two pharmaceuticals showed elevated risk in up to 13% of rivers affected by municipal efﬂuents. As an in-
tegrated model, our CFM is designed for application at very large scales with the primary goal of detecting high
risk zones. In regulatory frameworks, it can help screen existing or new chemicals entering themarket regarding
their potential impact on human and environmental health. Due to its high geospatial resolution, our CFM can
also facilitate the prioritization of actions, such as identifying regions where reducing contamination sources or
upgrading treatment plants is most pertinent to achieve targeted pollutant removal or to protect drinking
water resources.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)..
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contaminants released into the environment as a major threat to fresh-
water ecosystems (Millennium Ecosystem Assessment, 2005). Increas-
ingly, a multitude of toxicants enter the environment through sewage
treatment systems, which include substances and residues from indus-
trial products (e.g., additives, lubricants, ﬂame retardants), consumer
products (e.g., detergents, pharmaceuticals, personal care products),
synthetic and natural hormones (e.g., estrogens), illicit drugs and
nanomaterials (Schwarzenbach et al., 2006; Kümmerer, 2011; Khan
and Nicell, 2012; Khan and Nicell, 2014; Khan et al., 2014;).
This situation creates an urgent need to evaluate exposure of aquatic
life and humans to these chemicals. Inmost countries, regulatory frame-
works require new chemicals entering the market to undergo an envi-
ronmental risk assessment. In general, assessment of risk is
accomplished through exposure and effectmodeling, wherein exposure
modeling predicts environmental concentrations (Predicted Environ-
mental Concentration; PEC), and effect assessment deﬁnes levels
through which these environmental concentrations have no effect on
living organisms (Predicted No-Effect Concentration; PNEC). PEC values
higher than PNEC indicate unacceptable risk (Khan and Nicell, 2010;
Roos et al., 2012).
Many traditional methodologies assume that substances are emitted
in a standard environment with pre-deﬁned environmental characteris-
tics and use a constant per-capita discharge rate and dilution factors
based on country-wide averages (Keller et al., 2014). For example, this
approach is currently applied in the EuropeanUnion System for the Eval-
uation of Substances (EUSES; Vermeire et al., 1997; Attias et al., 2005).
This simpliﬁed method, however, does not account for spatial variation
in consumption, population distribution, physio-geographic characteris-
tics (such as hydrology and seasonality), wastewater treatment capabil-
ities, and environmental removal mechanisms (Pistocchi et al., 2012).
Any of these factors can result in environmental concentrations ranging
over several orders of magnitude, creating localized “contaminant hot-
spots” in the environment. Some researchers proposed in-situ substance
measurements to reﬁne simple non-spatial risk assessments; but mea-
surements are generally limited by high cost, time-consuming imple-
mentation, and lack of robust analytical methods (Pistocchi et al., 2012).
Contaminant fate models (CFMs), which combine Geographic Infor-
mation Systems and water quality models, have emerged as an addi-
tional research tool to estimate environmental concentrations of
chemicals and exposure of biota to these substances (Johnson et al.,
2008; Cowan-Ellsberry et al., 2009). CFMs mitigate some shortcomings
of current exposure and risk assessment methods (i.e., measurements,
non-spatial models), which can be summarized as follows:
1. CFMs have a strong spatial component; i.e. they take into account
population size and distribution, river network complexity and its
accumulating effects, and local river ﬂow dynamics that can differ
substantially from the emission point and across the streamnetwork.
2. CFMs are particularly useful for measuring analytically challenging
chemicals (e.g. nanoparticles), whose environmental quality stan-
dard is below current analytical capabilities(e.g., ethinylestradiol)
and those known to act as mixtures (e.g., estrogens).
3. For large spatial assessments, logistical and ﬁnancial challenges often
prohibit comprehensive sampling acrosswatersheds,makingmodel-
ing the only viable option. Once set up, the CFM can be repeatedly
used to address a wider range of similar contaminants without re-
quiring signiﬁcant additional model adjustments; however some
contaminants exhibit complex environmental interactions that re-
quire modeling speciﬁc processes beyond those usually considered
in CFMs (e.g. Liao et al., 2015; Rehmann and Soupir, 2009).
4. In addition to descriptive modeling, where the model outcome sim-
ulates concentrations under current ﬂow conditions, CFMs can be
used for predictive modeling such as when assessing a chemicalunder different climate or emission scenarios. Furthermore, CFMs
can aid in normativemodeling (“optimizing”) in order to answer pol-
icy questions. For example, CFMs can be used to determinewhere in-
terventions should be targeted in river systems or to highlight
wastewater treatment plants where upgrading would considerably
reduce in-river concentrations.
In general, two different approaches exist - multimedia or single-
media models. Multimedia models (EUSES; Vermeire et al., 1997;
Attias et al., 2005) simulate chemical sources and fate across different
environmental compartments (air, water, soil), but are generally difﬁ-
cult to parameterize, spatially coarse, and do not allow for site-speciﬁc
predictions. Single-media approaches have been used to predict single
substance concentrations in river networks at high spatial resolution,
such as GREAT-ER (Feijtel et al., 1998), ISTREEM (Wang et al., 2000),
LF2000-WQX (Williams et al., 2012), PhATE (Anderson et al., 2004),
the MAPPE model (Pistocchi et al., 2012), and the GWAVA model
(Johnson et al., 2013). Such models are particularly well-designed for
down-the-drain chemicals and have been applied to chemical exposure
assessments in various studies (Atkinson et al., 2009; Cunninghamet al.,
2009; Hannah et al., 2009; Ort et al., 2009; Cunningham et al., 2012;
Hosseini et al., 2012; Johnson et al., 2013). Thesemodels share common
assumptions and similar key mechanisms. Reasonable per capita emis-
sion estimates of contaminant mass entering individual wastewater
treatment plants (WWTP) can be gained using the average per-capita
consumption of a compound of interest and, if relevant, adjusting for
human metabolism. The contaminant mass released by individual
WWTPs into speciﬁc river reaches can be estimated using the average
per-capita emissions, knowledge of the local population served by a
WWTP, and adjusting for removal during treatment, where relevant
(Keller et al., 2006). As for chemical routing in the hydrological system,
advection is assumed to be the dominant dilution mechanism, which
can be modeled effectively using stream length, velocity, discharge,
and a decay function (Pistocchi et al., 2010). Predicted environmental
concentrations (PECs) are subsequently evaluated based on accumulat-
ed load and discharge for each river reach.
The prediction error from these models have consistently fallen
within oneorder ofmagnitudewhen compared to actualmeasurements
and, in most cases, range within 2–4 times of the measured environ-
mental concentration (Johnson et al., 2008). As such, and with these
limitations inmind, they are deemed suitable for screening-level risk as-
sessments. However, CFM set-up involves a number of complexities,
particularly the need for quality cross-boundary hydrographic base
maps, including realistic hydrological predictions throughout the river
network, consumption variability information, and the chemical's fate
in the system, such as wastewater treatment efﬁciency and environ-
mental decay. These requirements lead to limited model deployment
to regions where such high quality information is not readily available.
In Canada, a geospatially explicit large-scale tool to predict aquatic con-
centrations of substances released from wastewater systems at sufﬁ-
cient spatial resolution to support risk assessment activities for
regulatory frameworks, such as required under the Canadian Chemical
Management Plan (Minister of the Environment and Minister of
Health, 2006), doesn't exist.
To address this need, in this study, we present a new contaminant
fate model that is based on the integration of three components: the
HydroSHEDS database (Lehner et al., 2008) which provides the river
network of themodel; downscaled runoff estimates from the global hy-
drological model WaterGAP (Alcamo et al., 2003; Döll et al., 2003)
which serve as the hydrological baseline data; and the HydroROUT
river routingmodel (Lehner and Grill, 2013) which includes the routing
component. We designed our model to predict environmental concen-
trations for a wide range of chemicals within a complex aquatic net-
work. After initial setup and validation, we applied the model to
assess 15 pharmaceuticals in regard to their environmental concentra-
tions and eco-toxicological risk for the Saint Lawrence River Basin.
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The Canadian provinces of Quebec and Ontario were the core study
area, with a focus on the Saint Lawrence River (Fig. 1). We also included
all river reaches (‘contributing areas’) that enter the two provinces, as
deﬁned by the watershed delineation from the HydroSHEDS database
in order to generate a hydrologically complete river network. Cross-
boundary watersheds include parts of the United States of America
(USA) from that states of Minnesota, Wisconsin, Michigan, Ohio, New
York, and Vermont, but most of these USA watersheds drain into the
Great Lakes before their ﬂow arrives in Canada. We assumed complete
dilution of contaminants in large water bodies, hence the USA tribu-
taries to the Great Lakes were not considered to pose an immediate
risk for Ontario and Quebec. Therefore, in terms of chemical mass bal-
ance calculations, we excluded efﬂuents from wastewater treatment
plants located in contributing areas south of the Great Lakes. There
are, however, parts of New York and Vermont that drain directly into
the lower St. Lawrence River that are likely more relevant contaminant
sources from the USA, so we included these regions in the pilot model
version. In total, 1198 WWTPs were geo-located and incorporated in
our study (Fig. 1).
Fig. 2 provides a conceptual overview of the study. A geospatial ex-
posure and fate model embedded in a Geographic Information System
calculated PECs, based on a cascade of input and removal mechanisms.
To determine the PNEC, the lowest available eco-toxicological endpoint
was divided by an assessment factor (AF) (Fig. 2). The magnitude of AF
is dependent on the nature of the lowest available eco-toxicological
endpoint (i.e. whether it was obtained after an acute or chronic expo-
sure) (EU-TGD, 2003). The comparison of PEC against PNEC was used
to locate river network areas with elevated environmental risk (PEC/
PNEC N1).
We used the pharmaceutical carbamazepine to validate model per-
formance by comparing it with Canadian measurements from a litera-
ture review. Following the validation of the model, we evaluated the
risk posed by 15 pharmaceuticals using the model's output and the
eco-toxicological benchmarks.Fig. 1. The study area included areas of the provinces of Quebec and Ontario, Canada, as well a
Lawrence River below Kingston, Ontario). Color markers represent distribution of wastewater2.1. Baseline hydrography and discharge estimates
To simulate environmental contaminant concentrations, an ade-
quate characterization of discharge of Canadian rivers that receive
wastewater efﬂuentswas required. This ensures that the dilutive capac-
ity of the receiving waters is appropriately parameterized to generate
predicted environmental concentrations suitable for contaminant risk
assessments.
We used the HydroSHEDS database (Lehner et al., 2008), a publicly
available global suite of data layers representing river network topology
and watershed boundaries, to provide the baseline hydrographic data.
HydroSHEDS deﬁnes ﬂow directions at 500 m pixel resolution that are
used for water and substance transport simulation in a routing model
called HydroROUT (Lehner and Grill, 2013).
The current version of HydroROUT does not simulate runoff genera-
tion (i.e., the vertical water balance) within themodel itself. Instead, we
employed decoupled, external runoff estimates provided by the global
integrated water balance model WaterGAP (Alcamo et al., 2003; Döll
et al., 2003; model version 2.1 as of 2012). WaterGAP provides runoff
estimates ofmonthly averages from 1961 to 1990 (i.e., the ‘climate-nor-
mal’ period as deﬁned by the World Meteorological Organization) at a
0.5° grid resolution. We used these runoff estimates with geospatial
downscaling methods to disaggregate the large grid cells into 500 m
pixels and then accumulate the runoff along the HydroSHEDS river net-
work. To evaluate the downscaled discharge estimates, we compared
long-term averages and low ﬂow indicators to the reported values of
57 selected HYDAT gauging stations (Environment Canada, 2012); for
selection criteria see Section S1 of the Supplementary information.
The results conﬁrmed a very strong correlation (R2 = 0.982; see
Section S1 for graph and more details).
The risk from chemical substances in surface waters is usually
assessed under low ﬂow conditions for which the daily Q90 ﬂow
(i.e., the ﬂow exceeded 90% of the time) is a frequently-used indicator
(e.g., Environment Canada and Health Canada, 2009). Typically, Q90 is
calculated from daily discharge measurements, but as the WaterGAP
runoff estimates are given as monthly time series, we substituteds some parts of the United States (hydrologically-connected areas draining into the Saint
treatment plants by state and province.
Fig. 2. Conceptual overview of the risk assessment approach used in this study. The exposure and fate model is described in the study methodology section of this paper.
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erage ﬂow of the lowest month in the long-term annual ﬂow regime.
To explore the validity of this approach, we ﬁrst tested and conﬁrmed
a strong relationship between (daily) Q90 and Q90-MONTH for ob-
served HYDAT ﬂows by performing a linear regression analysis (R2 =
0.967). Then, we applied a second linear regression to test the correla-
tion of Q90-MONTH between observed HYDAT and simulated
HydroROUT values, which was slightly lower (R2 = 0.902; see
Section S1 for graph and more details).
As expected, the associated error for low ﬂow conditions is higher
than for long-term average discharges. Differences between modeled
and reported low ﬂows can vary by up to one order of magnitude, espe-
cially for smaller rivers. Accordingly, the uncertainty for predicting
contaminant concentrations for low ﬂow conditions is increasing. Nev-
ertheless, in terms of contaminationmodeling, we consider this range of
error still tolerable for general screening and risk assessment analysis,
assuming the goal of such assessments is to derive environmental con-
centrations within a factor of 10 (USEPA, 1996; Anderson et al., 2004).
2.2. Exposure model
2.2.1. Pharmaceutical emission model
The pharmaceutical emission model calculates emissions from the
annual per capita consumption and the number of inhabitants served
by the treatment plant. We calculated domestic contributions to
WWTPs by:
L Sð ÞWWTP ¼ CN Sð ÞTP  1msð Þ
  PTP ð1Þ
where L(S)WWTP is the total load arriving at theWWTP, CN(S)TP is the per
capita consumption of the pharmaceutical s of the connected popula-
tion, PTP is the total population connected to the WWTP, andms is the
fraction of pharmaceutical s that is metabolized in the human body.However, at the time of this study, the data for consumption on the in-
dividual treatment plant level CN(S)TP was not available. Therefore, we
created Canada-wide per capita consumption averages for all 15 phar-
maceuticals from total Canadian market sales data in 2006 (IMS
Brogan, 2007b, a) divided by the population totals for Canada in 2012
(Statistics Canada, 2014). We give further details on the boundary con-
ditions for each chemical in Table 1.
2.2.2. Wastewater treatment plant model
The geospatial locations and relevant attributes for wastewater
treatment plants located in Quebec and Ontario were obtained from
provincial environmental ministries. For wastewater treatment plants
located in Vermont and New York, geospatial locations and relevant at-
tribute data were extracted from the United States Environmental Pro-
tection Agency's Clean Watersheds Needs Survey (USEPA, 2010). In
total we assembled a database of the locations and characteristics of
1198 WWTPs (Fig. 1); see Supplementary information, Section S2 for
more details.Wedid not target industrial,mining or agricultural sources
in this study. The location, name, average daily ﬂow, treatment technol-
ogy and population served were given as attributes of eachWWTP. We
manually located (i.e., “snapped”) the wastewater treatment plants to
the appropriate HydroSHEDS river reach using satellite imagery and
other mapping sources as guideline information. Utilizing expert judg-
ment, we classiﬁed the treatment plants into the following categories:
no treatment, primary treatment, lagoon treatment, and secondary
treatment.
Depending on the type of treatment plant and compound simulated,
the environmental load is reduced prior to release, as described by:
L Sð ÞEFF ¼ L Sð ÞWWTP  R Tð ÞTP ð2Þ
where L(S)EFF is the mass of the substance in the efﬂuent from the
WWTP following treatment, L(S)WWTP is the incoming chemical load
Table 1
Parameter values used for the calculation of the source and fate of pharmaceuticals.
Pharmaceutical
Per capita consumption
in Canadaa
Metabolic
lossb
Removal in primary
treatment plantsc
Removal in secondary
treatment plantsd
Instream degradation
constant
Predicted no-effect
concentrationn
CNTP ms R1TP R2TP k PNEC
μg/cap·d Fraction Fraction Fraction day−1 ng/L
5-Fluorouracil 45 0.22 0.07 0.41 0.35e 200
Anastrozole 1 0.24 0.04 0.06 0.00f 1000
Atenolol 960 0.88 0.11 0.40 0.02–0.03f 148,000
Azithromycin 260 1.00 0 0 0.00g 9.4
Bicalutamide 20 0.48 0.04 0.05 0.00f 1000
Carbamazepine 1890 0.17 0 0.09 0.01h 500
Diazepam 24 0.11 0 0 0.00i 100
Diclofenac 760 0.24 0.01 0.42 0.29j 100
Ethinylestradiol (EE2) 1.1 0.43 0.21 0.84 0.07k 0.035
Fulvestrant 0.013 b0.19 0.65 0.72 0.00g 0.57
Hydrochlorothiazide 1160 1.00 0 0 0.00g 1000,000
Quetiapine 855 0.03 0.09 0.12 0.04l 10,000
Sulfamethoxazole 1410 0.30 0.003 0.50 0.04j 590
Tamoxifen 22 0.09 0.26 0.26 0.35m 22
Trimethoprim 310 0.79 0.10 0.25 0.00g 240,000
a IMS Brogan (2007a, 2007b) and Statistics Canada (2014).
b Khan and Nicell (2015) with the exception of Carbamazepine, which is based on the work of Cunningham et al. (2010).
c Khan (2015).
d Khan (2015) with the exceptions Carbamazepine and Trimethoprim, which are based on the work of Cunningham et al. (2010) and Straub (2013), respectively.
e Straub (2010).
f AstraZeneca (2013).
g Assumed to be zero.
h Cunningham et al. (2010).
i Straub (2008).
j Andreozzi et al. (2003).
k Caldwell et al. (2010).
l Fass (2015b).
m Fass (2015a).
n Derived in Supplementary information section S3.
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and R(T)TP is the removal efﬁciency in theWWTP of the compound, de-
pending on the type of removal, T.
2.3. River and lake routing model
At a 500m resolution, theHydroSHEDS database containsmore than
400,000 river reacheswith an average length of 2.8 kmwithin the study
area. A subset of 11,426 river reaches with a total length of 30,506 km
are affected by upstream efﬂuent from wastewater treatment plants.
We then integrated a comprehensive lake dataset, the Surface Water
BodyDatabase (SWBD;NASA/NGA, 2003) into the river network to rep-
resent lakes larger than 1 km2 in surface area (894 lakes are affected by
wastewater treatment plants out of a total of 171,856 lakes). SWBD in-
cludes vectorized lake polygons that were digitized as part of the Shut-
tle Radar Topographic Mission (SRTM) at a 30 m resolution. We also
estimated and validated lake volumes using GISmethods, based on cor-
relations with lake surface area and surrounding topography (Pistocchi
and Pennington, 2006; Hollister and Milstead, 2010).
We used HydroROUT's processing engine for mass balance calcula-
tions in the river and lake network. For river reaches, we followed a
‘plug-ﬂow’ approach (Pistocchi et al., 2010); that is, a ‘plug’ of substance
mass (the amount of contaminant released from the treatment plant) is
accumulated downstream as the sum of the input from the current and
all upstream reaches ﬂowing into the current reach. The river network
was processed iteratively in the hydrological order from source to
sink. The outﬂow mass balance for each river reach was calculated as:
PEC Sð ÞREACH ¼
∑
i
L Sð ÞEFF þ∑
j
L Sð ÞREACH
 !
 d
QREACH
ð3Þwhere PEC(S)REACH represents the environmental concentration at the
end of the river reach for compound s, as the mass inﬂux sum
L(S)EFF from all wastewater treatment plants i located anywhere on
the river reach with ﬂow QREACH, and the total mass L(S)REACH from all
upstream reaches j. Chemical substance degradation in the river body,
if applicable, is expected to decrease at a rate proportional to its concen-
tration, as reﬂected by the environmental decay factor d.We calculated
it based on ﬁrst-order decay d=e-ktwhere t is the time a plug of water
travels through the river reach, and k is a ﬁrst-order rate constant,
which determines the rate of environmental decay.
Travel time t is derived by dividing river reach length by the average
velocity within the river reach. This corresponds to the average reten-
tion time in each individual river reach; i.e., the time a plug of ﬂuid
needs to travel from the beginning to the end of the river segment.
We approximated velocity following an empirically-derived formula
(Allen et al., 1994):
v ¼ 1:07 QREACH0:1035 ð4Þ
where v is the velocity inm/swithin the river reach andQREACH is the dis-
charge in m3/s. Note that for simplicity we used average discharge (as
provided by the downscaled WaterGAP discharge estimates) instead of
the required ‘bankfull discharge’. The differences resulting from this lim-
itation should result in slightly lower velocities but are deemed accept-
able given the general limitations of the approach of Allen et al. (1994)
and considering the nature of this study as a screening type assessment.
As an initial measure in this study, we modeled each lake as a single
completely stirred tank reactor (Mihelcic et al., 2010):
PEC Sð ÞLAKE;OUT ¼ PEC Sð ÞLAKE;IN 
QLAKE
QLAKE þ kVLAKE
ð5Þ
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let, PEC(S)LAKE , IN represents the inﬂowing concentration from all river
sources, QLAKE is the discharge in m3/s entering the lake, k is the decay
constant for the contaminant in the lake, and VLAKE is the lake volume.
We used the same constant k for both lake and river decay. Future
models may improve onmodeling lakes by incorporating a “tank-in-se-
ries” approach (Shanahan and Harleman, 1984; Anderson et al., 2004).
2.4. Dilution factors and percent wastewater in river
We calculated dilution factorsDFWWTP of eachWWTP as the ratio be-
tween the downscaled river ﬂow at theWWTP location and the report-
ed discharge leaving each WWTP:
DFWWTP ¼ VRiver þ VWWTPVWWTP ð6Þ
where VRiver is the ﬂow volume in the river reach where the treatment
plant is located, and VWWTP is the sewage treatment plant efﬂuent
volume.
2.5. Environmental concentrations and risk assessment
In total, we selected 15 pharmaceuticals for environmental risk as-
sessment. The selected set comprised those pharmaceuticals for which
sufﬁcient eco-toxicological data was available in literature.With the ex-
ception of antibiotics, we considered a pharmaceutical to have sufﬁcient
eco-toxicological data if a chronic No Observed Effect Concentration
(NOEC) for ﬁsh was available for its exposure. For antibiotics, the avail-
ability of an endpoint for cyanobacteria was required before it could be
deemed to have sufﬁcient data. The reasons for this data availability re-
quirement was that ﬁsh appear to be the most sensitive taxon to non-
antibiotic pharmaceuticals (Fent et al., 2006; Khan and Nicell, 2009),
while cyanobacteria are the most sensitive taxon to antobiotics (Ebert
et al., 2011).
Subsequently, we predicted river concentrations for each chemical
using the parameterization given in Table 1 for both low ﬂow and aver-
age ﬂow conditions. In addition, we calculated risk indices for river
reaches by calculating the ratio between predicted environmental con-
centrations (PEC) and the predicted no effect concentration (PNEC) are
estimated in Supplementary information Section S3.
In general, PEC/PNEC N1 is indicative of unacceptable risk (EU-TGD,
2003; Khan and Nicell, 2010; Roos et al., 2012). Finally, we plotted the
risk indices as density curves for each chemical to further explore the
potential eco-toxicological risk of the chemical.
2.6. Testing of model performance
2.6.1. Model calibration, uncertainty and sensitivity
Contaminant fate models often simulate multiple substances with
differing environmental behaviors. Due to the wide range of input pa-
rameters, some of which can span several orders of magnitude, a cali-
bration for each individual contaminant is difﬁcult, time consuming,
and limited by sparse observational data. Even if such calibration is
achieved, an improvement over un-calibrated models is not always
guaranteed (Webster and Mackay, 2003). For these reasons, CFMs are
typically not calibrated but, rather, the PECs are based solely on the
input parameters (i.e., substance use, metabolism, removal, in-stream
decay).
Given the simpliﬁed, large-scale study design and the steady-state
approach of the current model implementation, we expect signiﬁcant
uncertainties due to the lack of understanding of the behavior of some
chemicals, and possibly signiﬁcant unaccounted variability regarding
input variables of the system. For example, inter-annual and seasonal
ﬂow changes increase the range of concentrations in the river system
and concentrations may be exceptionally high during extreme lowﬂow events. A second example is consumption variability such as
those arising from cross-country or regional differences in consumption
patterns, or temporal changes in consumption, for example the use of
ﬂumedication duringpandemics (Singer et al., 2013). And, as a third ex-
ample, the removal efﬁciency of a treatment plant may be variable; that
is, it can be substantially lower for combined sewer overﬂow systems
which allow some of the wastewater to be discharged untreated to sur-
face waters in case of high storm water volumes (Anne-Sophie et al.,
2015).
The model's prediction error related to variability is difﬁcult to esti-
mate, especially considering the fact that multiple, relatively unstudied
pharmaceuticals are to be modeled. Nevertheless, variability can be
accounted for, to some degree, in a sensitivity analysis by performing
Monte-Carlo simulations (Callahan, 1996) in which random values are
selected for key variables from pre-deﬁned probability density func-
tions for a large number of model runs. Generally, each variable uses a
speciﬁc probability density function, and the variation boundaries for
each pharmaceutical are determined individually based on the mean
and deviation (e.g., +/−0.5 standard deviation). However, due to the
lack of information at this time on the speciﬁc variability of these vari-
ables and each pharmaceutical, we used a simpler Monte-Carlo ap-
proach in which we ﬁxed minimum and maximum variability using a
single relative threshold for all variables and pharmaceuticals (we
used a 50% deviation from the mean), and drew random values from a
triangular probability distribution within the deﬁned variability bound-
aries. For example, if the discharge at a speciﬁc river reach was 5 m3/s,
the Monte-Carlo module randomly selected a value between 2.5 m3/s
and 7.5 m3/s from a triangular probability distribution. While this does
not allow for conﬁdence interval calculations, it does provide a sense
of themodel boundaries and allowed us to preliminary estimate the rel-
ative contribution of the input variables to the models` sensitivity. This
preliminary sensitivity analysis should nevertheless be replaced by a
more standard approach once better information about parameter var-
iability is obtained in subsequent studies.2.6.2. Corroboration of mass balance model
Experimental corroboration of the simulated PECs with ﬁeld mea-
surements would be unfeasible for a contaminant fate model that as-
sesses multiple chemicals and over such large spatial domains.
Furthermore, in the case of many emerging contaminants, suitable lab-
oratory methods currently do not exist or have not been developed. In
previous studies, contaminant fate models that share similar character-
istics have performed reasonably well without calibration for a wide
range of substances (Anderson et al., 2004).
In this study, we use common approaches for contaminant fate
model corroboration (Feijtel et al., 1998; Anderson et al., 2004;
Aronson et al., 2012). That is, we used cumulative frequency plot com-
parisons to evaluate mass balance module performance for one chemi-
cal; namely, carbamazepine (CBZ). CBZ, a commonly prescribed drug in
Canada (Khan and Nicell, 2015), undergoes relatively low removal in
WWTPs and is characterized by surface water persistence, making it a
good candidate for the validation of our mass balancemodel. The initial
conditions that drive the mass balance model for CBZ are shown in
Table 1.
Similar to the approach taken by others (e.g. Cunningham et al.,
2009), we used cumulative probability distributions to evaluate mea-
sured concentrations in Canadian rivers. We calculated cumulative dis-
tributions for numerous CBZ measurements as reported in the
literature. In total, we included 373 reported samples from 15 different
Canadian studies, including: Metcalfe et al. (2003); Miao and Metcalfe
(2003); Brun et al. (2006); Hua et al. (2006); Lissemore et al. (2006);
Lajeunesse and Gagnon (2007); MacLeod et al. (2007); Yargeau et al.
(2007); Viglino et al. (2008); Garcia-Ac et al. (2009); Viglino et al.
(2009); Li et al. (2010); Rahman et al. (2010); Tabe et al. (2010);
Waiser et al. (2011). We plotted the concentrations as cumulative
831G. Grill et al. / Science of the Total Environment 541 (2016) 825–838frequency curves that included non-detects and followed the same pro-
cedure for our model simulations to allow direct comparison.
Finally,we used point-by-point validation (e.g., Feijtel et al., 1998) to
compare the simulated concentrations from our model to the observed
concentrations measured at speciﬁc point locations in the river net-
work. Ideally, ﬁeld observations should be collected following a speciﬁc
and structured monitoring campaign. In this study, however, we used
only observed concentrations from two studies reporting on the envi-
ronmental presence of CBZ, one peer-reviewed study by Lajeunesse
and Gagnon (2007) and one Master's Thesis (Kormos, 2007).
3. Results
3.1. Model Corroboration
Fig. 3 shows a quantitative comparison between observed and sim-
ulated CBZ concentrations. Roughly 52% of samples across 15 studies re-
ported the detection of CBZ in surface waters (lakes and bays were
excluded). The observed and simulated concentrations plotted against
each other show relatively good agreement. The observed concentra-
tions fall within the minimum/maximum (min/max) range of the
Monte-Carlo simulations for both average and low ﬂow conditions.
The 95th percentile concentrations for CBZ were 13 ng/L (min 6 - max
29), 31 ng/L (11–65), and 85 ng/L under simulated average and low
ﬂow conditions, and for observed concentrations, respectively.
Due to the limited availability of geo-referenced measurements, we
could only conduct point-by-point validations at a few locations, as re-
ported by Lajeunesse and Gagnon (2007) and Kormos (2007); further
details are provided in the Supplementary information, Section S4.
Lajeunesse and Gagnon (2007) measured upstream and at distances
of up to 8 km downstream of the Montreal wastewater treatment
plant in the St. Lawrence River. The measurements of Lajeunesse and
Gagnon (2007) represent low ﬂow conditions and indicate that the
Montreal WWTP contributes strongly to the surface waterFig. 3. Cumulative frequency plot with minimum, maximum, and average concentrations
of carbamazepine for all reaches of the river network. Black and gray colors represent av-
erage ﬂow conditions; red and orange represent low ﬂow conditions. Ranges are comput-
ed based on 500Monte-Carlo simulations with random variation of parameters up to 50%
for substance usage, river discharge, and in-stream decay. Also plotted are observed con-
centrations for carbamazepine in Canadian surface waters, compiled from 15 studies
reporting the analysis of 373 samples for the presence of carbamazepine. Cumulatively,
carbamazepine was detected in 52% of the samples analyzed (non-detects are included
in the graph).concentrations of carbamazepine. This observation is replicated (albeit
at lower magnitude) in our model by the sharp increase of concentra-
tions in the St. Lawrence River below the location of Montreal's
WWTP (Table 2).
The study by Kormos (2007) reported raw surface water concentra-
tions of carbamazepine at two drinking water plants in the Grand River
Basin, Ontario and included detailed river discharge at the time of mea-
surement (see Supplementary information, Section S4 for details). The
comparison between observed and simulated ﬂow showed good overall
agreement between HYDAT's reported low and average ﬂow values
with our model (Table 3) although the average ﬂow is simulated nota-
bly higher than observed at Facility B. We then compared simulated
concentrations under low ﬂow conditions with predicted environmen-
tal concentrations from our model (Table 3). Despite the differences in
modeled discharge for one of the stations, in general, we observed a
good agreement between observed and simulated concentrations.
3.2. Dilution factors
Many screening-level risk assessment models are built on a hypo-
thetical “representative” scenario, based on apparently conservative as-
sumptions regarding environmental dilution in multiple water bodies.
Typically, such models for Canada assume that a conservative risk as-
sessment can be performed by using a default dilution factor (DF) of
10 (HC/EC, 2010). In the past, the suitability of such an assumption
had not been conﬁrmed for Canada. However, the model we developed
here is particularly suited to perform such an evaluation.
Under lowﬂow conditions, our results indeed show that 87%percent
of DFs of theWWTPs discharging into rivers are higher than 10 (Fig. 4),
suggesting that this value is a reasonable assumption for conservative
screening level assessments where risk management prioritization is
the goal. However, our results also show that the actual risk varies sub-
stantially depending on the hydrological conditions of speciﬁc loca-
tions: 118 WWTPs showed low (1 to 5) to medium (5 to 10) DF
values, suggesting potentially elevated risk downstream of these loca-
tions (Fig. 5).
3.3. Environmental risk assessment
We assessed environmental risk for the 15 pharmaceuticals selected
for the study area (Fig. 6 and Table 4). Of the 15 pharmaceutical evalu-
ated, the release of the antibiotic azithromycin, the nonsteroidal anti-
inﬂammatory drug diclofenac and the exogenous estrogen used in
birth control pills, ethinylestradiol (EE2), were found to present risk to
the receiving aquatic environment. The geospatially disaggregated con-
centrations of the antibiotic azithromycin under low ﬂowconditions are
shown in Fig. 7. Rivers showed elevated concentrations over extensive
lengths. On average, the Monte-Carlo runs indicated that azithromycin
showed PEC concentrations higher than its PNEC in 13% of the affected
river reaches with a minimum of 6% and a maximum of 25% affected.
Under average ﬂow conditions, azithromycin still triggered risk in
6.5% (min: 1.7%; max: 14%) of the river courses.
Geospatial concentrations of EE2 under low ﬂow conditions are
shown in Fig. 8. EE2 showed average PEC concentrations higher than
PNEC in 2.6% (min: 0.6%; max; 6.0%) of the affected river reaches
(Table 4). Under average ﬂow conditions, EE2 triggered risk in 0.8%
(min: 0.1%; max: 2.5%) of the river courses. We assumed PNEC for EE2
to be equal to the environmental quality standard developed by the
EU (SCHER, 2011). The risk predicted for EE2 release is lower than that
predicted by Johnson et al. (2013) for a number of countries in
Europe. The reason for this may be higher per capita EE2 consumption
in parts of Europe compared to Canada (Johnson et al., 2013) and
lower dilution levels that are available in Europe compared to Canada
for treated efﬂuents from WWTPs upon their release to the environ-
ment (Keller et al., 2014).
Table 2
Simulated and observed carbamazepine concentrations (ng/L) in the St. Lawrence River near Montreal, Quebec.
0.5 km
upstream of
WWTP
0.5 km downstream of
WWTP
2.5 km downstream of
WWTP
4.5 km downstream of
WWTP
8 km downstream of
WWTPa
Lajeunesse and Gagnon
(2007)
0.8 7.4 5 4 3.5
Modeled in this study 0.77 1.7 1.7 1.7 2.0
a Note: This location includes the load from two additional treatment plants and from the Miles Iles River.
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PNEC) N 1) to 0.04% (min: 0%; max: 0.3%) of the river length affected
by discharges of WWTPs (see Table 4).
The Monte-Carlo assessment, with a relatively conservative evalua-
tion of 50% variability for all three variables, produced a factor 2.5 to 6
difference between minimum and maximum concentrations across
three pharmaceuticals (azithromycin, ethinylestradiol, and diclofenac;
see Section 6 of the Supplementary information). An evaluation of a
wider range of variability would result in substantial non-linear in-
creases in the upper concentration boundaries and corresponding in-
creases in the number of river reaches in which risk is signiﬁcant. To
disentangle the relative contributions of the key variables of hydrology,
consumption and environmental decay to the range of outcomes, we
ran an additional sensitivity analysis for the three pharmaceuticals
that triggered risk. The analysis showed that hydrology contributes
most to overall variability, especially causing the upper boundaries to
increase disproportionally. Variability in consumption causes the
range of outcomes to increase to a lesser extent than hydrological vari-
ability but to expand upper and lower boundaries more equally. Vari-
ability in environmental decay contributed little to the combined
variability and seems to be negligible if the environmental decay is
low to begin with, such as in the case of EE2.
4. Discussion
As a ﬁrst indicator of potential impact, we calculated the percentage
of wastewater in river ﬂow by accumulating the efﬂuent ﬂows of all
WWTPs. The results pinpoint geographic hotspots of elevated generic
risk that may be targeted in management plans to improve the waste-
water treatment infrastructure or reduce consumption and disposal of
certain chemicals upstream.
We then estimated risks for 15 pharmaceuticals and found quite
high risk for azithromycin. To better appraise risk posed by the aquatic
release of azithromycin, it is worth discussing the manner in which its
PNEC was estimated (see SI, Section S3). We estimated azithromycin's
PNEC by dividing an acute endpoint for cyanobacteria with an applica-
tion factor (AF) of 100 (SI, Section S3). We deemed this necessary at
this point in time, since the available endpoint for the critical taxon
(i.e., cyanobacteria) was an acute endpoint. Therefore the apparent
risk posed by azithromycin may partially reside in the high AF required
to evaluate its PNEC. Therefore, a chronic endpoint for the exposure of
azithromycin to cyanobacteria needs to be developed. Further we con-
servatively assumed that azithromycin is not degraded upon it release
to environment; this assumption also warrants further veriﬁcation.Table 3
Comparison between observed and simulated long-term ﬂow (m3/s) and between ob-
served and simulated carbamazepine (CBZ) concentrations (ng/L) at two drinking water
stations on the Grand River, Ontario. The concentration for the “observed Q90-MONTH
low ﬂow”was approximated by taking the average ﬂow of themonths of low ﬂow across
samples of both facilities.
Location
Average ﬂow (m3/s)
Q90-month ﬂow
(m3/s)
CBZ conc. (ng/L)
Observed Simulated Observed Simulated Observed Simulated
Facility A 38 42 14 11 22 26
Facility B 58 91 20 25 50 48Nevertheless, currently available data indicates that azithromycin re-
lease presents a potentially problematic risk to the study area.
The risk of EE2 was also found to be elevated. The PNEC for EE2 was
developed with an AF of 2 (SCHER, 2011), which is indicative of the fact
that there is a high degree of conﬁdence in the ecotoxicological data
available for ﬁsh exposure to EE2. Therefore, the predications made
here suggest that EE2 may be presenting an unacceptable risk to a
small number of river reaches in the study area. That said, others have
suggested PNECs for EE2 at levels much higher than that proposed by
the EU (Laurenson et al., 2014). However, the assessment of risk
posed by EE2 when evaluated on its own also has limitations because
EE2 is known to act with other endogenous estrogens to result in ﬁsh
developing intersex characteristics (Williams et al., 2009).
At this stage ofmodel development, wewere unable to quantify var-
ious uncertainties due to inherent modeling and measurement errors.
Such uncertainties can result from errors in the HydroROUT model or
in the underlying global runoff estimates and their downscaling to
higher resolution river networks. Although we found good overall
agreement between the downscaled discharge estimates and observa-
tions at gauging stations, remaining uncertainties include errors in the
routing process (e.g., related to ﬂow velocity, channel geometry, ﬂow at-
tenuation) and errors due to inadequately represented ﬂow regulation
structures. Human controlled ﬂow regulation, such as accomplished by
dams and reservoirs are common in the study area, possibly causing sig-
niﬁcant misrepresentation of low ﬂow conditions. Furthermore, diverg-
ing (bifurcating) river channels (which may converge again further
downstream) lead to errors in HydroROUT as the underlying ﬂow direc-
tion scheme is currently unable to represent these situations. Also, in theFig. 4. Cumulative frequency plot of dilution factors. A total of 888WWTPswere included;
WWTPs that discharge into lakes, or discharge seasonally were excluded.
Fig. 5.Map of dilution factors under low ﬂow conditions (Q90-MONTH).
833G. Grill et al. / Science of the Total Environment 541 (2016) 825–838current model version we estimate variable ﬂow velocities based on the
approach of Allen et al. (1994). This approach is simplistic and introduces
uncertainty regarding the time available for in-stream decay and remov-
al rates. This method is subject to further veriﬁcation and uncertainty
analysis; howeverwe do not consider it amain contributor to uncertain-
ty in our present study. Finally, our hydrological simulations are limited
to steady-state, decoupled discharge routing processes and assume in-
stantaneous and full mixing of efﬂuents in the river reach. While these
simpliﬁcations compromise the validity of local results, we believe that
the approach is nonetheless adequate for comparative large scale assess-
ments and screening purposes.Fig. 6. Risk indices (PEC/PNEC) for simulated pharmaceuticals under low ﬂow conditions. Risk I
dicted No-Effect Concentration (PNEC) (i.e., PEC/PNEC).The validation using carbamazepine revealed differences between
observed and simulated 95th percentile concentrations, which can be at-
tributed, in part, to the limited data point availability across different
river sizes, but more likely to the fact that measurements are generally
biased towards collecting samples from surface waters with high con-
centrations, such as downstreamplumes ofwastewater treatment plants
(Hannah et al., 2009). Furthermore, almost no study records river ﬂow at
the time of measurement, which further complicates the comparison. A
possible improvement to the validation methodology could be achieved
by comparing cumulative probability plots for speciﬁc regions with sim-
ulated and reported concentrations from similar river reaches.ndex is calculated as the ratio of Predicted Environmental Concentration (PEC) to the Pre-
Table 4
Minimum, mean and maximum 95th percentile concentrations (ng/L) of pharmaceuticals in rivers under average ﬂow conditions (AVG-YEAR) and low ﬂow conditions (Q90-MONTH).
‘Min’ and ‘Max’ percentile concentration refer to the results of the Monte-Carlo runs, representing boundary concentrations, whereas ‘mean’ refers to the average of Monte-Carlo runs.
Also shown are the percentages of river length affected downstream of WWTPs (total length of rivers 36,419 km) that exceed PNEC concentrations (Risk Index (PEC/PNEC) N 1). Sub-
stances that trigger risk in any form are indicated in bold. PNECs for the pharmaceuticals are estimated in Supporting information, Section S3.
Pharmaceutical
PNEC
(ng/L)
Average ﬂow scenario
(AVG-YEAR)
Low ﬂow scenario
(Q90-MONTH)
Mean 95th percentile conc. (ng/L)
Risk Index (PEC/PNEC) N 1
(% river length)
Mean 95th percentile conc. (ng/L)
Risk Index (PEC/PNEC) N 1
(% river length)
5-Fluorouracil 200
0.25
(min: 0.09;
max: 0.57)
0
0.65
(min: 0.25;
max: 1.46)
0
Anastrozole 1000
0.010
(min: 0.005;
max: 0.024)
0
0.03
(min: 0.01;
max: 0.05)
0
Atenolol 148,000
26
(min: 11);
max: 57)
0
65
(min: 27;
max: 138)
0
Azithromycin 9.4
12
(min: 4.9;
max: 27)
6.5
(min: 1.7;
max: 14)
28
(min: 11;
max: 60)
13
(min: 6;
max: 25)
Bicalutamide 1000
0.42
(min: 0.17;
max: 0.93)
0
1.01
(min: 0.41;
max: 2.20)
0
Carbamazepine 500
124
(min: 4.9;
max: 27)
0
30
(min: 12;
max: 66)
0
Diazepam 100
0.13
(min: 0.05;
max: 0.28)
0
0.29
(min: 0.12;
max: 0.61)
0
Diclofenac 100
4.6
(min: 1.8;
max: 11)
0.03
(min: 0;
max: 0.09)
12
(min: 4.7;
max: 27)
0.04
(min: 0;
max: 0.3)
Ethinylestradiol (EE2) 0.035
0.0076
(min: 0.0030;
max: 0.0170)
0.8
(min: 0.1;
max: 2.5)
0.0191
(min: 0.0078;
max: 0.0419)
2.6
(min: 0.6;
max: 6.0)
Fulvestrant 0.57
0.00005
(min: 0.00002;
max: 0.00010)
0
0.00014
(min: 0.00006;
max: 0.000300)
0
Hydrochlorothiazide 1000,000
56
(min: 22;
max: 122)
0
126
(min: 51;
max: 269)
0
Quetiapine 10,000
0.9
(min: 0.4;
max: 2.0)
0
2.2
(min: 1.0;
max: 4.8)
0
Sulfamethoxazole 590
11
(min: 4.6;
max: 25)
0
31
(min: 12;
max: 65)
0
Tamoxifen 22
0.06
(min: 0.02;
max: 0.14)
0
0.15
(min: 0.06;
max: 0.33)
0
Trimethoprim 240,000
9.8
(min: 3.9;
max: 21)
0
22
(min: 9.3;
max: 48)
0
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Monte-Carlo simulation module is currently based on simpliﬁed as-
sumptions to generate combinations of parameter sets. We believe,
however, that better uncertainty calculation implementations can fur-
ther improve model output conﬁdence.
We have not addressed the temporal variation in product consump-
tion and associated chemical emissions. Consumption may vary inter-
annually or seasonally, change between different days of the week, or
follow diurnal ﬂuctuations (Kormos, 2007; Snip et al., 2014). These pat-
terns in product consumption are currently disregarded since such in-
formation is typically not available. More insight into speciﬁc chemical
variations could improve sensitivity analysis settings and allow for
more realistic results. In caseswhere substance consumption differs sig-
niﬁcantly by region, the accuracy of predictions could be increased by
using local sales data as a proxy. Sales data is available at individual
province or city levels or even at ﬁner scales (e.g., from the ﬁrm IMS
Health/IMS Brogan); however, the costs associated with the acquisition
of this data prohibited their inclusion in this study.Finally, our contaminant fatemodel does not currently include input
from atmospheric deposition, erosion, surface runoff, or from the dis-
charge of non-treated wastewater. The latter could be a signiﬁcant con-
tributor since the connection of population to sewage treatment plants
is incomplete in the study region.5. Conclusions
Wedeveloped aﬁrst version of a newgeospatial chemical fatemodel
that combines a global, high-resolution hydrographic database
(HydroSHEDS) with a river routing model (HydroROUT) to estimate
sources and fate of chemicals. The performance of the model was vali-
dated in a preliminary study focusing on the Saint Lawrence River
Basin.We simulated environmental concentrations for 15 pharmaceuti-
cals and identiﬁed potentially elevated risk for the estrogen
ethinylestradiol (EE2) and the antibiotic azithromycin in a moderate
and large number of river reaches, respectively.
Fig. 7. Simulated azithromycin concentrations in rivers under low ﬂow conditions (A) and associated risk indices (PEC/PNEC) assuming a PNEC of 9.4 ng/L (B). The results for simulated
azithromycin concentrations and risk under average ﬂow conditions are given in section S5 of the Supplementary information (Fig. S5).
835G. Grill et al. / Science of the Total Environment 541 (2016) 825–838Based on the results presented, we believe that our model is capable
of realistically estimating in-river contaminant concentrations for the
purpose of screening for down-the-drain chemicals, especially consid-
ering that a typical goal of such models is to simulate concentrations
that are within an order of magnitude of measured concentrations.
The downscaled discharge estimates used in our chemical fate
model are in good overall agreement with data from gauging stations,
although further improvement can be made to represent low ﬂows
more accurately. We have shown that monthly discharge data has the
potential to be substituted as a ﬁrst-order proxy for commonly used
daily low ﬂow metrics such as Q90, yet uncertainties need to be tested
more thoroughly for this approach.Ourmodel is unique in incorporating a large-scale database of lakes,
and by taking into account lake removal processes,which are particular-
ly important in Canada's lake-rich environments. Future model devel-
opment should include more validation of lake volume estimates and
test other lake removal models.
A future goal is to extend this model to the pan-Canadian scale to
support the implementation of the Canadian Chemical Management
Plan. Based on the experiences of the current study, we consider this
goal achievable if substantial work is conducted to gain greater conﬁ-
dence in the simulated and downscaled discharge estimates, especially
focussing on low ﬂow metrics, and provided that enough resources are
available to co-reference the location of contaminant sources, such as
Fig. 8. Simulated ethinylestradiol concentrations in rivers under low ﬂowconditions (A) and associated risk indices (PEC/PNEC) assuming PNEC of 0.035 ng/L (B). The results for simulated
ethinylestradiol concentrations and risk under average ﬂow conditions are given in section S5 of the Supplementary information (Fig. S6).
836 G. Grill et al. / Science of the Total Environment 541 (2016) 825–838WWTPs, to the river network, which took a substantial share of
the model development time. The seamless hydrographic database
(i.e., river network and discharge estimates) facilitated modeling
of cross-border contributions from sources outside Canada and general-
ly enables us to develop the model within and across national
boundaries.
We anticipate that this model can serve other functions as well. For
example, it could be used in conjunction with on-going research to:
(1) evaluate the importance of a number of emerging contaminants;
(2) evaluate the cumulative effects of pollutant loadings originating
from urban communities and industries (e.g., hospitals, mining, petro-
leum, pulp and paper, and etc.) across entire watersheds at large scales;and (3) simulate the potential impacts of speciﬁc events that can result
in signiﬁcant particular pollutant emissions across watersheds for rela-
tively short periods of time (e.g., during the extensive use of speciﬁc
pharmaceuticals during pandemics).
Our model aims to enhance the scientiﬁc understanding of the lega-
cy of contaminants at large and to create a leading, large-scale contam-
inant fatemodel that can serve as a unique tool to study risks and future
threats related to cumulative efﬂuents of substances from domestic, ag-
ricultural, or industrial sources; screen for critically impacted areas; and
test or optimize mitigation scenarios. If extended to the national scale,
the model can support the implementation of the Canadian Chemical
Management Plan by adding a geospatial risk assessment component.
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